PBR Nachrichten

 

The financing was raised in a Series A round led by RA Capital Management, with participation from Forbion, Canaan Partners and other investors. Porustobart is a second-generation, Fc-enhanced The post Solstice Oncology secures $225m to drive porustobart's development for cancer appeared first on Pharmaceutical Business review....

Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA, all joining The post TwoStep Therapeutics secures $62.5m funding to advance TS-104 appeared first on Pharmaceutical Business review....

The new facility expands the company's capabilities in inflammation, oncology and data science. Gilead currently employs 11,000 people in the US, with more than 7,400 based in California The post Gilead launches research facility in US for new medicine development appeared first on Pharmaceutical Business review....

RXRG001 is a circular ribonucleic acid (RNA) therapy encoding human aquaporin-1, a protein involved in fluid transport. The therapy is encapsulated within lipid nanoparticles and directly administered to The post FDA grants RMAT designation to RiboX's RXRG001 for xerostomia appeared first on Pharmaceutical Business review....

The Liverpool Accelerate Laboratory was developed with the LSTM-led iiCON: Infection Innovation Consortium and received funding from the Liverpool City Region Combined Authority. It is due to open The post LSTM opens $23m robotic AI lab for infection research appeared first on Pharmaceutical Business review....

The purchase adds an established hypertension brand to Novartis' cardiovascular range. Novartis India's board cleared the deal, after which the company signed an asset purchase agreement and trademark The post Novartis India acquires Pfizer brands for $132m appeared first on Pharmaceutical Business review....

This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. The clearance applies when an estrogen receptor 1 (ESR1) mutation is The post FDA approves AstraZeneca's Etcamah combo for advanced breast cancer appeared first on Pharmaceutical Business review....

The 72,300ft² site is said to be the largest single-site contract development and manufacturing organisation (CDMO) facility in North America for radiopharmaceutical development to date. It supports low-to-high The post AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario appeared first on Pharmaceutical Business review....

The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and The post Superluminal Medicines secures $60m to advance rare obesity therapy appeared first on Pharmaceutical Business review....

The agreement gives Médunik Canada immediate responsibility for Diacomit's sales, marketing, and medical affairs activities throughout the country. It aims to leverage Médunik Canada's network and rare disease The post Médunik and Biocodex sign exclusive agreement for Diacomit in Canada appeared first on Pharmaceutical Business review....

The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen's RenNano platform, in its research and development (R&D) activities focused on neuroscience therapeutics. It The post Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule appeared first on Pharmaceutical Business review....

The deal allows Novartis to exercise multiple options for exclusive global rights to develop subcutaneous versions of several of its products employing the berahyaluronidase alfa enzyme, also known The post Novartis signs deal with Alteogen for drug delivery appeared first on Pharmaceutical Business review....

The partnership aims to integrate Weave Bio's AI tools with Takeda's regulatory experience to streamline workflows within the regulatory process. The joint effort began with the use of The post Takeda and Weave Bio collaborate on AI-driven automation in drug development appeared first on Pharmaceutical Business review....

The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers. Ono Pharmaceutical The post Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology appeared first on Pharmaceutical Business review....

This marks the first FDA-approved treatment for ET in nearly 30 years. The approval is based on data from the global Phase III SURPASS ET trial, which demonstrated The post PharmaEssentia's Besremi receives FDA approval for ET appeared first on Pharmaceutical Business review....

These proceeds will support the planned and ongoing studies of Kazia's lead investigational therapy, paxalisib, in triple-negative breast cancer, hormone receptor positive/human epidermal growth factor receptor 2 negative The post Kazia closes oversubscribed offering to fund paxalisib's clinical development appeared first on Pharmaceutical Business review....

The agreement arises as part of BioXcel Therapeutics' voluntary Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware, initiating a court-supervised sale of the The post Teva Pharmaceuticals to acquire BioXcel assets for up to $125m appeared first on Pharmaceutical Business review....

The round was led by an undisclosed strategic investor. New investor RA Capital Management also participated, along with existing investors that included HanKang Capital, Qiming Venture Partners and The post AusperBio raises $120m to progress hepatitis B therapies appeared first on Pharmaceutical Business review....

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 April 2027. Also known as bimatoprost grenod or NCX 470, K-911 is The post FDA to review Kowa Pharmaceuticals' NDA for glaucoma eye drop K-911 appeared first on Pharmaceutical Business review....

The designation covers CMT as a whole and is not restricted to specific subtypes. The RPDD programme seeks to promote the development of therapies for rare, serious or The post FDA grants RPDD to ReviR's RTX-117 for CMT appeared first on Pharmaceutical Business review....